MIAMI – Nov. 5, 2015 – International law firm Greenberg Traurig, P.A. recently represented SciVac Therapeutics Inc. (TSX:VAC)(OTCQX:SVACF) in its agreement to acquire VBI Vaccines Inc. (NASDAQ:VBIV). Upon consummation of the acquisition, the combined, commercial-stage company will have both a licensed hepatitis B ("HBV") vaccine and a pipeline of preventative and therapeutic vaccine candidates.
Following the acquisition, Greenberg Traurig’s longtime client OPKO Health, Inc. will be the largest shareholder of the combined company. OPKO is a multinational biopharmaceutical and diagnostics company, led by Chairman and Chief Executive Officer Dr. Phillip Frost.
The Greenberg Traurig deal team was led by Miami Corporate & Securities Shareholders Robert L. Grossman and Drew M. Altman. Grossman also serves as also Co-Chair of the firm’s Israel Practice. Other deal team members include:
-
Indira Sordo, Miami, Corporate & Securities
-
Samantha D. Glover, Miami, Corporate & Securities
-
Michael R. Einig, Miami, Tax
-
Seth J. Entin, Miami, Tax
-
Barry J. Schindler, New Jersey, Intellectual Property & Technology
-
Elysa B. Goldberg, New Jersey, Intellectual Property & Technology
-
Luis Fernandez De La Vara, Miami, Corporate & Securities
SciVac Therapeutics Inc., headquartered in Rehovot Israel, is in the business of developing, producing and marketing biological products for human healthcare. SciVac's flagship product, Sci-B-Vac™, is a recombinant third-generation hepatitis B vaccine. SciVac also offers contract development and manufacturing services to the life sciences and biotechnology markets.